Loading resource…

Washington University
Septic shock results from a dysregulated host response to infection and remains a significant cause of global morbidity and mortality. While standard care of septic shock remains protocolized due to improved outcomes with timely antibiotic and fluid administration, recent data have informed a more nuanced, individualized approach to sepsis management. Increasing evidence suggests that septic shock results from dynamic phases of immune dysregulation that may provide targets for precision therapy and data from large clinical trials have informed a complementary approach to fluid and vasopressor administration.
Sign in to open
Answers use this document only.
Your first question is free.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

LEFT VENTRICULAR-ARTERIAL COUPLING IN SEPTIC SHOCK: A PHYSIOLOGICAL REVIEW
Same clinical topic · Critical Care

CENTRAL VENOUS PRESSURE REVISITED: PHYSIOLOGY, PITFALLS, MISCONCEPTIONS, AND MODERN CLINICAL INTERPRETATION IN CRITICAL CARE
Same clinical topic · Critical Care

HOW I PERSONALIZE FLUID THERAPY IN SEPTIC SHOCK?
Same clinical topic · Critical Care

PRINCIPLES OF FLUID MANAGEMENT
Same clinical topic · Critical Care

ANEMIA OF CRITICAL ILLNESS: A CONCISE DEFINITIVE REVIEW IN CRITICAL CARE
Same clinical topic · Critical Care

NON-INTERVENTIONAL FOLLOW-UP VERSUS FLUID BOLUS IN RESPONSE TO OLIGURIA IN HEMODYNAMICALLY STABLE CRITICALLY ILL PATIENTS: A RANDOMIZED CONTROLLED PILOT TRIAL
Same clinical topic · Critical Care

LONG-TERM EFFECTS OF RESTRICTION OF INTRAVENOUS FLUID IN ADULT ICU PATIENTS WITH SEPTIC SHOCK
Same clinical topic · Critical Care

ASSOCIATION BETWEEN COMBINATION ANTIBIOTIC THERAPY AS OPPOSED TO MONOTHERAPY AND OUTCOMES OF ICU PATIENTS WITH PSEUDOMONAS AERUGINOSA VENTILATOR-ASSOCIATED PNEUMONIA: AN ANCILLARY STUDY OF THE IDIAPASON TRIAL
Same clinical topic · Critical Care

INTERFERON GAMMA - 1B FOR THE PREVENTION OF HOSPITAL - ACQUIRED PNEUMONIA IN CRITICALLY ILL PATIENTS: A PHASE 2, PLACEBO - CONTROLLED RANDOMIZED CLINICAL TRIAL
Same clinical topic · Critical Care